Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Community Clin Res CTR
1819
mi
from 91732
Anderson, IN
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Community Clin Res CTR
1819
mi
from 91732
Anderson, IN
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Midwest Institute for Clinical Research
1791
mi
from 91732
Indianapolis, IN
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Midwest Institute for Clinical Research
1791
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associated LLC
1183
mi
from 91732
Newton, KA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associated LLC
1183
mi
from 91732
Newton, KA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
1186
mi
from 91732
Wichita, KA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
1186
mi
from 91732
Wichita, KA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Best Clinical Trials, LLC
1655
mi
from 91732
New Orleans, LA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Best Clinical Trials, LLC
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Clinsite LLC
1929
mi
from 91732
Ann Arbor, MI
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Clinsite LLC
1929
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Premier Research
2395
mi
from 91732
Trenton, NJ
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Premier Research
2395
mi
from 91732
Trenton, NJ
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Metrolina Internal Medicine/Internal Medicine Research
2102
mi
from 91732
Charlotte, NC
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Metrolina Internal Medicine/Internal Medicine Research
2102
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Pharmquest
2150
mi
from 91732
Greensboro, NC
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Pharmquest
2150
mi
from 91732
Greensboro, NC
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Wake Research Associates, LLC
2214
mi
from 91732
Raleigh, NC
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Wake Research Associates, LLC
2214
mi
from 91732
Raleigh, NC
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Dayton Clinical Research
1894
mi
from 91732
Dayton, OH
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Dayton Clinical Research
1894
mi
from 91732
Dayton, OH
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Oklahoma City Clinic - Midwest City / Radiant Research Inc
1171
mi
from 91732
Midwest City, OK
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Oklahoma City Clinic - Midwest City / Radiant Research Inc
1171
mi
from 91732
Midwest City, OK
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Clinical Studies
744
mi
from 91732
Eugene, OR
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Clinical Studies
744
mi
from 91732
Eugene, OR
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Detweiler Family Medicine and Associates, PC
2367
mi
from 91732
Lansdale, PA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Detweiler Family Medicine and Associates, PC
2367
mi
from 91732
Lansdale, PA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Suburban Research Center
2363
mi
from 91732
Media, PA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Suburban Research Center
2363
mi
from 91732
Media, PA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Tekton Research
1212
mi
from 91732
Austin, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Tekton Research
1212
mi
from 91732
Austin, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Family Medicine Associates of Texas - ACRC Trials
1214
mi
from 91732
Carrollton, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Family Medicine Associates of Texas - ACRC Trials
1214
mi
from 91732
Carrollton, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Avant Research Associates LLC
1434
mi
from 91732
Port Arthur, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Avant Research Associates LLC
1434
mi
from 91732
Port Arthur, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Radiant Research, Inc
1188
mi
from 91732
San Antonio, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Radiant Research, Inc
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Wasatch Clinical Research
565
mi
from 91732
Salt Lake City, UT
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Wasatch Clinical Research
565
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
National Clinical Research, Inc.
2261
mi
from 91732
Richmond, VA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
National Clinical Research, Inc.
2261
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Northwest Clinical Research Center
959
mi
from 91732
Bellevue, WA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Northwest Clinical Research Center
959
mi
from 91732
Bellevue, WA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Noble Clinical Research, LLC
429
mi
from 91732
Tucson, AZ
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Noble Clinical Research, LLC
429
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Bandera Family Health Care
1179
mi
from 91732
San Antonio, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Bandera Family Health Care
1179
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Manna Research Vancouver
1082
mi
from 91732
Vancouver,
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Manna Research Vancouver
1082
mi
from 91732
Vancouver,
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Alan Graff, MD, PA
2315
mi
from 91732
Fort Lauderdale, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Alan Graff, MD, PA
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Gulfcoast Clinical Research Center
2209
mi
from 91732
Fort Myers, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Gulfcoast Clinical Research Center
2209
mi
from 91732
Fort Myers, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Oklahoma City Clinic - Edmond / Radiant Research Inc
1168
mi
from 91732
Edmond, OK
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Oklahoma City Clinic - Edmond / Radiant Research Inc
1168
mi
from 91732
Edmond, OK
Click here to add this to my saved trials
WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure.
The Effect of Potatoes on Potassium Retention, Acid Base Balance, and Blood Pressure
Status: Enrolling
Updated:  12/31/1969
Department of Nutrition Science Purdue University
1756
mi
from 91732
West Lafayette, IN
Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure.
The Effect of Potatoes on Potassium Retention, Acid Base Balance, and Blood Pressure
Status: Enrolling
Updated: 12/31/1969
Department of Nutrition Science Purdue University
1756
mi
from 91732
West Lafayette, IN
Click here to add this to my saved trials
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Suburban Hospital
2277
mi
from 91732
Bethesda, MD
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Suburban Hospital
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
Inhaled Nitric Oxide and Transfusion Therapy for Patients With Sickle Cell Anemia and Secondary Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Endothelial Cell Dysfunction in Pulmonary Hypertension
Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Endothelial Cell Dysfunction in Pulmonary Hypertension
Endothelial Cell Dysfunction in Pulmonary Arterial Hypertension: Biomarkers, Mechanisms of Disease and Novel Therapeutic Targets
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation
The Effect of Aortic Impedance on Myocardial Relaxation
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
1654
mi
from 91732
Madison, WI
Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation
The Effect of Aortic Impedance on Myocardial Relaxation
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
1654
mi
from 91732
Madison, WI
Click here to add this to my saved trials
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Cardiopulmonary Function Assessment and NO Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Cardiopulmonary Function Assessment and NO Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Connecticut
2491
mi
from 91732
Farmington, CT
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Connecticut
2491
mi
from 91732
Farmington, CT
Click here to add this to my saved trials
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
2281
mi
from 91732
Washington,
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Stanford University
329
mi
from 91732
Palo Alto, CA
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Stanford University
329
mi
from 91732
Palo Alto, CA
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Iowa
1527
mi
from 91732
Iowa City, IA
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Iowa
1527
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center
2578
mi
from 91732
Boston, MA
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Wayne State University
1965
mi
from 91732
Detroit, MI
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Wayne State University
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of New Mexico
648
mi
from 91732
Albuquerque, NM
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of New Mexico
648
mi
from 91732
Albuquerque, NM
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
RTI International
2204
mi
from 91732
Durham, NC
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
RTI International
2204
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Duke University
2203
mi
from 91732
Durham, NC
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Duke University
2203
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve University, Rainbow Babies and Children's Hospital
2036
mi
from 91732
Cleveland, OH
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve University, Rainbow Babies and Children's Hospital
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
1221
mi
from 91732
Dallas, TX
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated:  12/31/1969
University of Utah
572
mi
from 91732
Salt Lake City, UT
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
Status: Enrolling
Updated: 12/31/1969
University of Utah
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Long-term Single-arm Open-label Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials